Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns

Ishita Kamboj, Chelsea Gorsline, Aneela Majeed, Dilek Ince, Jordan Snyder, Hira Shaikh, Abdullah Mohammad Khan, Kimberly M Green, Shebli Atrash, Faiz Anwer, Claire Yun Kyoung Ryu Tiger, Omar Alkharabsheh, Prerna Mewawalla, Al-Ola Abdallah, Barry Paul, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 7178.

https://doi.org/10.1182/blood-2024-208036

Published: 2024

Journal Articles

Efficacy of BCMA T-Cell Engagers (TCE) Vs. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Following BCMA-Directed Therapies, Relapsed/Refractory Multiple Myeloma: The Chicken or the Egg Dilemma

Blood (2024) 144 (Supplement 1): 7098.

https://doi.org/10.1182/blood-2024-207398

Published: 2024

Journal Articles

Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 5170.4.

https://doi.org/10.1182/blood-2024-211018

Published: 2024

Journal Articles

Cytomegalovirus Reactivation in Patients with Multiple Myeloma Treated with Teclistamab: Risk Factors and Clinical Impact

Charles Pei, Lisa Blackburn, Nidhi Sharma, Naresh Bumma, Abdullah Mohammad Khan, Srinivas Devarakonda, Elvira Umyarova, Don Benson, Ashley Rosko, Zeinab El Boghdadly, Francesca Cottini

Blood (2024) 144 (Supplement 1): 4717.

https://doi.org/10.1182/blood-2024-201519

Published: 2024

Journal Articles

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Blood (2024) 144 (Supplement 1): 2000.1.

https://doi.org/10.1182/blood-2024-200210

Published: 2024

Journal Articles

Comparative Effectiveness of Ciltacabtagene Autoleucel from the Cartitude-4 Trial Vs Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma - an Updated Overall Survival Analysis

Blood (2024) 144 (Supplement 1): 7089.

https://doi.org/10.1182/blood-2024-205383

Published: 2024

Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Isatuximab, Carfilzomib and Dexamethasone in the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Blood (2024) 144 (Supplement 1): 7088.

https://doi.org/10.1182/blood-2024-205189

Published: 2024

Journal Articles

Evaluation of Characteristics and Outcomes of Patients with Primary and Secondary Plasma Cell Leukemia Treated with Modern Therapies

Megan Broughton, Subodh Bhatta, Nidhi Sharma, Elvira Umyarova, Abdullah Mohammad Khan, Srinivas Devarakonda, Naresh Bumma, Ashley Rosko, Don Benson, Francesca Cottini

Blood (2024) 144 (Supplement 1): 6980.

https://doi.org/10.1182/blood-2024-206283

Published: 2024

Journal Articles

Building Inroads for Transplant Access: Bridging the Gap for Underserved Patients with Multiple Myeloma

Srinivas Devarakonda, Qiuhong Zhao, Don Benson, Francesca Cottini, Abdullah Mohammad Khan, Elvira Umyarova, Naresh Bumma, Nowshin Islam, Nidhi Sharma, Jessica Krok-Schoen, James L Fisher, Jesse J Plascak, Electra D Paskett, Ashley Rosko

Blood (2024) 144 (Supplement 1): 7865.

https://doi.org/10.1182/blood-2024-211200

Published: 2024

Journal Articles

Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7860.

https://doi.org/10.1182/blood-2024-210976

Published: 2024

Journal Articles

Second Primary Hematological Malignancy in Multiple Myeloma Patients Exposed to Lenalidomide and Autologous Stem Cell Transplantation

Justin Jiang, Joshua Galloway, Andrew Srisuwananukorn, Uma Borate, Nidhi Sharma, Naresh Bumma, Srinivas Devarakonda, Elvira Umyarova, Ashley Rosko, Abdullah Mohammad Khan, Don Benson, Francesca Cottini

Blood (2024) 144 (Supplement 1): 6954.

https://doi.org/10.1182/blood-2024-198754

Published: 2024

Journal Articles

A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Alma Habib, Abdullah Mohammad Khan, Mehak M Laharwal, Prerna Mewawalla, Marshall McKenna, Yun Kyoung Tiger, Hira Shaikh, Christopher Strouse, Kimberly M Green, James A Davis, Hamza Hashmi, Jordan Snyder, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Nausheen Ahmed, Al-Ola Abdallah, Shebli Atrash, Barry Paul, Reed Friend

Blood (2024) 144 (Supplement 1): 7037.

https://doi.org/10.1182/blood-2024-209283

Published: 2024

Journal Articles

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns

Ishita Kamboj, Jordan Snyder, Chelsea Gorsline, Dilek Ince, Aneela Majeed, Faiz Anwer, Hira Shaikh, Abdullah Mohammad Khan, Al-Ola Abdallah, Kimberly M Green, Shebli Atrash, Claire Yun Kyoung Ryu Tiger, Prerna Mewawalla, Barry Paul, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5040.

https://doi.org/10.1182/blood-2024-208349

Published: 2024

Journal Articles

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial

Ishita Kamboj, Darryl Chang, Alma Habib, Andrew Vegel, Emily Struble, Hira Shaikh, Christopher Strouse, James A Davis, Aliya Rashid, Kevin Graf, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Al-Ola Abdallah, Shebli Atrash, Abdullah Mohammad Khan, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 2411.2.

https://doi.org/10.1182/blood-2024-199187

Published: 2024

Journal Articles

Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

Darryl Chang, Alma Habib, Andrew Vegel, Emily Struble, Hira Shaikh, Christopher Strouse, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Abdullah Mohammad Khan, Al-Ola Abdallah, Nausheen Ahmed, Shebli Atrash, Manisha Bhutani

Blood (2024) 144 (Supplement 1): 2404.

https://doi.org/10.1182/blood-2024-208692

Published: 2024

Journal Articles

Lovesick: Examining Couples Health during Myeloma Transplant

Ashley Rosko, Don Benson, Francesca Cottini, Abdullah Mohammad Khan, Srinivas Devarakonda, Elvira Umyarova, Naresh Bumma, Lisa Blackburn, Cathie Atkinson, Juan Peng, Janice Kiecolt-Glaser, Lisa Christian

Blood (2024) 144 (Supplement 1): 285.

https://doi.org/10.1182/blood-2024-206199

Published: 2024

Journal Articles

A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Alma Habib, Nausheen Ahmed, Abdullah Mohammad Khan, Darryl Chang, Barry Paul, Hira Shaikh, Christopher Strouse, Emily Struble, Andrew Vegel, James A Davis, Kimberly M Green, Hamza Hashmi, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Joseph P. McGuirk, Al-Ola Abdallah, Shebli Atrash, Reed Friend

Blood (2024) 144 (Supplement 1): 2009.

https://doi.org/10.1182/blood-2024-208799

Published: 2024

Journal Articles

Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 2411.7.

https://doi.org/10.1182/blood-2024-204158

Published: 2024

Journal Articles

Improvement in Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience

Jordan Nunnelee, BA, Qiuhong Zhao, MS, Don M. Benson, Jr., MD PhD, Ashley E. Rosko, MD, Maria Chaudhry, MD, Naresh Bumma, MD, Abdullah Mohammad Khan, MBBS,MSc, Srinivas Devarakonda, MD, Yvonne A. Efebera, MD MPH, Nidhi Sharma, PhD

Blood (2019) 134 (Supplement_1): 4573.

https://doi.org/10.1182/blood-2019-121845

Published: 2019

Journal Articles

Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma

Francesca Cottini, MD, Nita Williams, Naresh Bumma, MD, Abdullah Mohammad Khan, MBBS, MSc, Maria Chaudhry, MD, Srinivas Devarakonda, MD, Yvonne A. Efebera, MD MPH, Don M. Benson, Jr., MD PhD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 5501.

https://doi.org/10.1182/blood-2019-129128

Published: 2019

NARROW

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns

Efficacy of BCMA T-Cell Engagers (TCE) Vs. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Following BCMA-Directed Therapies, Relapsed/Refractory Multiple Myeloma: The Chicken or the Egg Dilemma

Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Cytomegalovirus Reactivation in Patients with Multiple Myeloma Treated with Teclistamab: Risk Factors and Clinical Impact

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Comparative Effectiveness of Ciltacabtagene Autoleucel from the Cartitude-4 Trial Vs Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma - an Updated Overall Survival Analysis

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Isatuximab, Carfilzomib and Dexamethasone in the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Evaluation of Characteristics and Outcomes of Patients with Primary and Secondary Plasma Cell Leukemia Treated with Modern Therapies

Building Inroads for Transplant Access: Bridging the Gap for Underserved Patients with Multiple Myeloma

Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Second Primary Hematological Malignancy in Multiple Myeloma Patients Exposed to Lenalidomide and Autologous Stem Cell Transplantation

A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial

Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

Lovesick: Examining Couples Health during Myeloma Transplant

A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma

Improvement in Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience

Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only